Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing Through ReproTracker® Collaboration Charles River Laboratories International, Inc. (NYSE: CRL) and Dutch biotechnology company Toxys have announced a strategic…
HealthTap Joins LillyDirect® to Expand Virtual Primary Care Access for Diabetes Management HealthTap, a leading provider of virtual primary care services in the United States, has announced that it will…
RIBOMIC’s Umedaptanib Pegol Achieves Strong Growth Outcomes in Children with Achondroplasia: Phase 2 Data Support Advancement to Late-Stage Clinical Development RIBOMIC, Inc. (TOKYO: 4591), a Japan-based clinical-stage biotechnology company focused…
Celltrion Showcases Real-World Evidence Supporting Switch from IV to Subcutaneous Infliximab at UEG Week 2025 Celltrion, Inc., a global leader in biopharmaceutical innovation, today highlighted compelling real-world evidence supporting the…
Merz Therapeutics Strengthens European Footprint with Launch of New Affiliate in Poland Merz Therapeutics GmbH, a globally recognized leader in neurology-focused specialty pharmaceuticals, has officially announced the opening of its…
Aphios Corporation Awarded NIH Grant to Advance Botanical Drug Zindol® for Cancer-Related Nausea and Vomiting Aphios Corporation, a pioneer in the development of advanced botanical pharmaceuticals and nutraceuticals, has received…
bioAffinity Technologies Reports Record Third-Quarter 2025 Growth in CyPath® Lung Test Adoption, Driven by Expanding Clinical Use and Physician Confidence bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company pioneering…
Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical…
Allurion Publishes Landmark Peer-Reviewed Study Demonstrating Over 20% Total Body Weight Loss With Consecutive Use of Its Smart Capsule Allurion Technologies, Inc. (NYSE: ALUR), a global leader in developing innovative,…
DemeRx Secures $1.7 Million NIH Grant to Advance First-in-Class Neuroplastogen DMX-1001 for Alcohol Use Disorder DemeRx, Inc., a clinical-stage biopharmaceutical company committed to transforming addiction therapeutics through innovative neuroscience, announced…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies…
Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss…